Nothing Special   »   [go: up one dir, main page]

A geroprotector aims to affect the root cause of aging and age-related diseases, and thus prolong the life span of animals.[1][2] Some possible geroprotectors include melatonin,[3] carnosine,[4] metformin,[5] rapamycin,[6] nicotinamide mononucleotide (NMN)[7] and delta sleep-inducing peptide.[8]

Geroprotectors could belong to multiple classes depending on which of the hallmarks of aging they influence.

The distinction between geroprotectors and senotherapeutics is an evolving area of aging research. Geroprotectors broadly aim to target multiple mechanisms of aging, prolonging lifespan and healthspan by addressing the fundamental causes of aging. Senotherapeutics, on the other hand, are a subset of therapies that specifically target senescent cells, which are dysfunctional cells that accumulate with age and contribute to inflammation and age-related diseases.[9]

See also

edit

References

edit
  1. ^ Alexey Moskalev, Elizaveta Chernyagina, Anna Kudryavtseva & Mikhail Shaposhnikov (2017). "Geroprotectors: A Unified Concept and Screening Approaches". Aging and Disease. 8 (3): 354–363. doi:10.14336/AD.2016.1022. PMC 5440114. PMID 28580190.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  2. ^ Alexey Moskalev, Elizaveta Chernyagina, João Pedro de Magalhães & Alex Zhavoronkov (2015). "Geroprotectors.org: a new, structured and curated database of current therapeutic interventions in aging and age-related disease". Aging. 7 (9): 616–628. doi:10.18632/aging.100799. PMC 4600621. PMID 26342919.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  3. ^ Anisimov, VN; Popovich, IG; Zabezhinski, MA; Anisimov, SV; Vesnushkin, GM; Vinogradova, IA (2006). "Melatonin as antioxidant, geroprotector and anticarcinogen". Biochimica et Biophysica Acta (BBA) - Bioenergetics. 1757 (5–6): 573–89. doi:10.1016/j.bbabio.2006.03.012. PMID 16678784.
  4. ^ Boldyrev, AA; Stvolinsky, SL; Fedorova, TN; Suslina, ZA (2010). "Carnosine as a natural antioxidant and geroprotector: From molecular mechanisms to clinical trials". Rejuvenation Research. 13 (2–3): 156–8. doi:10.1089/rej.2009.0923. PMID 20017611.
  5. ^ Bulterijs, S (2011). "Metformin As a Geroprotector". Rejuvenation Research. 14 (5): 469–82. doi:10.1089/rej.2011.1153. PMID 21882902. S2CID 40645408.
  6. ^ Dumas, Sabrina N; Lamming, Dudley W (2020-01-01). "Next Generation Strategies for Geroprotection via mTORC1 Inhibition". The Journals of Gerontology: Series A. 75 (1): 14–23. doi:10.1093/gerona/glz056. ISSN 1079-5006. PMC 6909887. PMID 30794726.
  7. ^ Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice, Cell Metabolism 24, 795–806, December 13, 2016 ª 2016 Elsevier Inc.
  8. ^ Bondarenko, TI (2011). "Mechanism of delta-sleep inducing peptide geroprotective activity". Adv Gerontol. 24 (1): 80–92. PMID 21809625.
  9. ^ Al-Naggar, Iman M. A. (24 October 2020). "Senolytics: Targeting Senescent Cells for Age-Associated Diseases". Current Molecular Biology Reports. 6: 161–172 – via Springer.
edit